It is important to note that individual patient responses vary considerably, and the 'best tolerated' GLP-1 for one person may differ from another
One study using galactose-decorated PLGA NPs reported significantly enhanced hepatocyte uptake of encapsulated peptides, and suggested that adapting this system for semaglutide could further improve intrahepatic exposure and anti-steatotic efficacy [253]
State Legislative Landscape in 2025 Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date
Because it works through a different mechanism, LDN may be appropriate for patients whose weight management challenges have inflammatory or autoimmune components rather than purely metabolic ones
Rather, they are used to treat high body weight, high BMI, and some comorbidities associated with obesity for the long term. Are the pills as effective as the injectables
eClinicalMedicine 58 , 101962 (2023)
